Citigroup Issues Pessimistic Forecast for Zenas BioPharma (NASDAQ:ZBIO) Stock Price

Zenas BioPharma (NASDAQ:ZBIO) had its price target reduced by Citigroup from $43.00 to $41.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup’s price objective points to a potential upside of 75.06% from the company’s current price.

Several other research firms have also commented on ZBIO. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a report on Monday, December 29th. Morgan Stanley upped their price objective on shares of Zenas BioPharma from $19.00 to $21.00 and gave the company an “equal weight” rating in a report on Tuesday. Wall Street Zen upgraded shares of Zenas BioPharma from a “sell” rating to a “hold” rating in a research report on Saturday, February 21st. Guggenheim lifted their target price on shares of Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Evercore started coverage on shares of Zenas BioPharma in a report on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 target price on the stock. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $44.14.

Zenas BioPharma Price Performance

Shares of NASDAQ:ZBIO traded up $0.19 during midday trading on Tuesday, hitting $23.42. The company had a trading volume of 122,956 shares, compared to its average volume of 927,645. Zenas BioPharma has a twelve month low of $6.11 and a twelve month high of $44.60. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -3.30 and a beta of -1.96. The company has a debt-to-equity ratio of 0.37, a current ratio of 5.66 and a quick ratio of 5.66. The business’s 50-day simple moving average is $22.61 and its 200-day simple moving average is $27.12.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings data on Monday, March 16th. The company reported ($4.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by ($3.32).

Insider Activity at Zenas BioPharma

In related news, Director Hongbo Lu acquired 25,985 shares of the company’s stock in a transaction that occurred on Wednesday, February 11th. The stock was purchased at an average price of $22.50 per share, for a total transaction of $584,662.50. Following the transaction, the director owned 347,968 shares in the company, valued at $7,829,280. This trade represents a 8.07% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Patricia L. Allen bought 4,160 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The stock was purchased at an average cost of $26.36 per share, with a total value of $109,657.60. Following the purchase, the director directly owned 19,860 shares in the company, valued at $523,509.60. The trade was a 26.50% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 202,845 shares of company stock valued at $3,747,185 over the last quarter. Insiders own 16.50% of the company’s stock.

Institutional Trading of Zenas BioPharma

A number of hedge funds have recently bought and sold shares of the company. GF Fund Management CO. LTD. acquired a new position in Zenas BioPharma in the 4th quarter valued at $38,000. Quarry LP lifted its stake in shares of Zenas BioPharma by 34.5% during the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock worth $25,000 after purchasing an additional 291 shares during the period. Russell Investments Group Ltd. acquired a new stake in shares of Zenas BioPharma during the third quarter worth $30,000. CWM LLC boosted its holdings in shares of Zenas BioPharma by 48.3% during the fourth quarter. CWM LLC now owns 2,178 shares of the company’s stock worth $79,000 after purchasing an additional 709 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Zenas BioPharma in the fourth quarter valued at $95,000.

Zenas BioPharma News Summary

Here are the key news stories impacting Zenas BioPharma this week:

• Positive Sentiment: Secured up to $250 million in non‑dilutive, multi‑tranche debt financing from Pharmakon, which materially strengthens near‑term liquidity and supports upcoming regulatory filings and trials. Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $44 price target — signaling strong upside potential (large gap versus current price) and likely contributing bullish investor interest. Benzinga
• Positive Sentiment: Notable insider and institutional accumulation reported (multiple insider purchases and several large funds adding shares), which can signal management confidence and support the share price. Quiver Quantitative
• Neutral Sentiment: Company reiterated clinical and regulatory milestones (FDA/EMA submissions for obexelimab expected in 2026; ongoing/near‑term Phase‑3 activity for orelabrutinib and pipeline progress) — important catalysts but timing/outcomes remain uncertain. Corporate update & milestones
• Neutral Sentiment: Company granted inducement stock options and RSUs to new hires (235,700 options; 33,450 RSUs) — supports hiring and retention but introduces potential future dilution; viewed as operational rather than immediate material impact. Inducement Grants
• Negative Sentiment: Significant quarterly earnings miss: GAAP EPS of -$4.54 vs. consensus -$1.22 — the large shortfall raises near‑term profitability and guidance concerns and has negative implications for valuation. Earnings press release
• Negative Sentiment: Company disclosed an IPO‑related securities class action in its risk filings, which adds potential legal exposure and execution risk until resolved. TipRanks – Litigation risk

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.